including the absence of T cell help, the location of the dying cells (which in part dictates their engulfment by distinct dendritic cell (DC) subtypes), the maturation state of the DC ...

Hematologist-oncologist Mateo Mejia Saldarriaga, MD, combines clinical care with research aimed at helping patients with ...

Shares of Cartesian Therapeutics climbed after the company announced positive results in a phase 2b trial of its lead cell-therapy candidate. The stock was up 8.3% to $15.60 in morning trading Tuesday ...

What Are T Cell Engagers (TCEs ... teclistamab (Tecvayli) which targets B-cell maturation antigen (BCMA) for multiple myeloma ...

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

The following is a summary of “BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma,” published in ...

The method, called "Perturb-multiome," uses CRISPR to knock out the function of individual transcription factors across many blood cells at once. The researchers then perform single-cell analyses ...